2012-12-07

Liposomal amphotericin B as a treatment for human leishmaniasis

Expert Opinion on Emerging Drugs

by Balasegaram M, Ritmeijer K, Lima MA, Burza S, Ortiz Genovese G, Milani B, Gaspani S, Potet J, Chappuis F. Expert Opinion on Emerging Drugs, December 2012, Vol. 17, No. 4 , Pages 493-510

Click here to read the article / PDF

Latest scientific articles

Stay connected

Get our latest news, personal stories, research articles, and job opportunities.

International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Liposomal amphotericin B as a treatment for human leishmaniasis

Latest scientific articles

Strengthening health systems and clinical development capacities through effective partnerships: a case study of DNDi’s collaboration with the Leishmaniasis Research and Treatment Center in Ethiopia (2003–2022)

Efficacy and safety of oxfendazole in adults with Trichuris spp. infection in Pemba Island, Tanzania: a double-blind, phase 2a, randomised controlled trial

Deconvoluting the mode of action of antileishmanial aminopyrazoles through chemical mutagenesis

Rethinking Clinical Trial Design to Accelerate Therapeutics for Arboviral Epidemics

Stay connected

Learn more

Get in touch

Support us

Work with us